2,4-二氨基-5-氨甲基嘧啶 | 4458-18-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,4-二氨基-5-氨甲基嘧啶
• 英文名称: 5-(aminomethyl)pyrimidine-2,4-diamine
• 英文别名: 5-aminomethyl-pyrimidine-2,4-diamine；5-aminomethyl-pyrimidine-2,4-diyldiamine；5-Aminomethyl-pyrimidin-2,4-diyldiamin；2,4-Diamino-5-aminomethyl-pyrimidin
• CAS: 4458-18-8
• 化学式: C₅H₉N₅
• 分子量: 139.16
• InChiKey: GSCPVFNKSWRDMO-UHFFFAOYSA-N

物化性质

• 沸点：
  458.2±53.0 °C(Predicted)
• 密度：
  1.385±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,4-二氨基-5-氨甲基嘧啶 在 甲醇 、 sodium hydroxide 作用下， 生成 7-amino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidine-2-thione
  参考文献：
  名称：

  Chatterji; Anand, Journal Of Scientific and Industrial Research, 1959, vol. 18B, p. 272,277

  摘要：

  DOI：
• 作为产物：
  描述：

  2-硫乙基-4-氨基-5-氰基嘧啶 在 盐酸 、 乙醇 、 氨 作用下， 生成 2,4-二氨基-5-氨甲基嘧啶
  参考文献：
  名称：

  Matsukawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 417,443;dtsch.Ref.S.122,125

  摘要：

  DOI：

文献信息

• Lewis Acid-Catalyzed Synthesis of 4-Aminopyrimidines: A Scalable Industrial Process
  作者：Ulla Létinois、Jan Schütz、Ralph Härter、Rinke Stoll、Florian Huffschmidt、Werner Bonrath、Reinhard Karge

  DOI：10.1021/op300190s

  日期：2013.3.15

  Pyrimidine synthesis starting from acrylonitrile has been known since the 1960s. The new Lewis acid-catalyzed condensation reaction allows the synthesis of 4-aminopyrimidines starting from the easily accessible chemical acrylonitrile without the need for carcinogenic chemicals and costly derivatization in up to 90% yield. The method is versatile and applicable for industrial-scale synthesis of biologically

  自1960年代以来，就已知从丙烯腈开始合成嘧啶。新的路易斯酸催化的缩合反应可从易于获得的化学丙烯腈开始合成4-氨基嘧啶，而无需致癌化学物质，且衍生化成本高达90％。该方法用途广泛，可用于工业规模的生物相关物质的合成，例如维生素B1和甲氧苄啶。
• Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
  申请人：Dana-Farber Cancer Institute

  公开号：US07056911B1

  公开（公告）日：2006-06-06

  The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

  本发明涉及药物活性化合物，以及利用或包含其中一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物特别适用于治疗或预防与寄生虫感染相关的疾病，如肺孢子菌肺炎、弓形虫病、隐孢子虫病、利什曼病和疟疾。
• 2,4-Diamino-5-(4-methyl-5-β-hydroxyethylthiazolium chloride)-methylpyrimidine Hydrochloride, a New Analog of Thiamin
  作者：Wolfgang Huber

  DOI：10.1021/ja01251a060

  日期：1943.11
• Structure aided design of chimeric antibiotics
  作者：Tomislav Karoli、Sreeman K. Mamidyala、Johannes Zuegg、Scott R. Fry、Ernest H.L. Tee、Tanya A. Bradford、Praveen K. Madala、Johnny X. Huang、Soumya Ramu、Mark S. Butler、Matthew A. Cooper

  DOI：10.1016/j.bmcl.2012.02.019

  日期：2012.4

  The rise of antibiotic resistance is of great clinical concern. One approach to reducing the development of resistance is to co-administer two or more antibiotics with different modes of action. However, it can be difficult to control the distribution and pharmacokinetics of two drugs to ensure both concentrations remain within the range of therapeutic efficacy whilst avoiding adverse effects. Hybrid drugs, where two drugs are linked together with a flexible linker, have been explored, but the resultant large, flexible molecules can have poor bioavailability. We have developed a chimeric approach using click chemistry where the pharmacophores of two drugs are overlapped into a single smaller, more drug-like molecule. Design and selection of compounds were assisted by in silico structural docking. We prepared a series of compounds that include candidates showing activity against the targets of both trimethoprim; dihydrofolate reductase, and ciprofloxacin; DNA gyrase and topoisomerase IV. The resultant triazole containing molecules show modest, but broad spectrum activities against drug sensitive and resistant Gram-negative and Gram-positive bacteria, with no observable cytotoxicity. (C) 2012 Elsevier Ltd. All rights reserved.
• Notes- 2,4-Diamino-5-formylpyrimidine and 2,4-Diamino-5-hydroxymethylpyrimidine
  作者：Howard Tieckelmann、Robert Guthrie、J Nairn

  DOI：10.1021/jo01077a620

  日期：1960.7